This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ASLAN Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 0/6
ASLAN Pharmaceuticals has a total shareholder equity of $-18.0M and total debt of $26.5M, which brings its debt-to-equity ratio to -147.6%. Its total assets and total liabilities are $21.0M and $39.0M respectively.
Informations clés
-147.6%
Ratio d'endettement
US$26.52m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$18.40m |
| Fonds propres | -US$17.96m |
| Total du passif | US$38.95m |
| Total des actifs | US$20.99m |
Mises à jour récentes de la santé financière
Analyse de la situation financière
Passif à court terme: ASLN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: ASLN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: ASLN has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: ASLN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: ASLN has less than a year of cash runway based on its current free cash flow.
Prévisions de trésorerie: ASLN has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.9% each year.